중국 의약품 허가특허연계제도의 구축과 시사점

• 영문명: Establishment and Implications of Drug approval-Patent Linkage System in China
• 발행기관: 충북대학교 법학연구소
• 저자명: 복정정(Bu, Zhen Zhen) 신혜은(Shin, Hye Eun)
• 간행물 정보: 『과학기술과 법』제10권 제2호, 155~186쪽, 전체 32쪽
• 주제분류: 법학 > 법학
• 파일형태: PDF
• 발행일자: 2019.12.30

영문 초록

The introduction of China s drug approval-patent linkage system will have a significant impact on Korean companies from a long-term perspective. The pharmaceutical industry is an industry that cannot exist without protection from intellectual property rights. With the growing demand for geriatric care due to aging and the growth of the emerging markets for pharmaceuticals, the U.S., Europe and Japan are trying to strengthen the competitiveness of their industries by strongly protecting drug inventions. The largest drug market is by far the United States, but China is emerging as a new market. However, despite the various efforts, it is still difficult to implement the drug approval-patent linkage system in China, so it is difficult to realize the goal of fully resolving patent disputes in advance. Through the analysis of the Chinese drug approval-patent linkage system, this paper seeks to examine the problems of the current Chinese drug approval-patent linkage system and explore ways to resolve and prevent patent disputes related to medicine in advance before the release of generic drugs in China.

목차

Ⅰ. 들어가며

Ⅱ. 중국의 의약품 허가특허연계제도

Ⅲ. 중국 허가특허연계제도의 문제점

Ⅳ. 중국 의약품 허가특허연계제도에 현존하는 문제점 해결방안

Ⅴ. 결어

키워드

특허연계제도 제약산업 혁신 도입 제네릭 patent linkage system pharmaceutical industry innovation introduce generic drugs